SCHEMBL4594077

SCHEMBL4594077

O=C(O)C(=O)CCN1CCN(CCO[N+](=O)[O-])CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.39
ALDH1A1 P00352 9/20 0.39
TDP1 Q9NUW8 2/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MAPT P10636 1/20 0.37
APEX1 P27695 1/20 0.36
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
HTR1A P08908 1/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
HTT P42858 1/20 0.34
LMNA P02545 1/20 0.34
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GAA P10253 1/20 0.33
TP53 P04637 1/20 0.33
GLA P06280 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4594578 0.90 SMN1; SMN2 (0.39) KDM4EALDH1A1TDP1MMP2MMP9
SCHEMBL4594912 0.90 ALDH1A1 (0.38) KDM4EALDH1A1TDP1MAPTAPEX1
SCHEMBL4593996 0.89 MMP2 (0.39) KDM4EALDH1A1TDP1MMP2MMP9
SCHEMBL4588394 0.87 APEX1 (0.36) KDM4EALDH1A1TDP1MAPTAPEX1
SCHEMBL4593885 0.84 SMN1; SMN2 (0.39) KDM4EALDH1A1TDP1MMP2MMP9
SCHEMBL4594020 0.83 PAOX (0.38) KDM4EALDH1A1TDP1MMP2MMP9
SCHEMBL29528050 0.78 TSHR (0.39) KDM4EALDH1A1MMP2MMP9HTR1A
SCHEMBL4593088 0.78 SMN1; SMN2 (0.39) KDM4EALDH1A1TDP1APEX1MEN1
SCHEMBL2802284 0.77 MMP2 (0.36) KDM4EALDH1A1TDP1MMP2MMP9
SCHEMBL4593556 0.76 PAOX (0.38) KDM4EALDH1A1TDP1MAPTHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use NITROMED, INC. (US) 2008-11-20 US claimed
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use NITROMED, INC. (US) 2008-11-20 US disclosed
EP-1692107-A4 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2008-10-29 EP disclosed
EP-1692107-A2 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2006-08-23 EP disclosed
WO-2005060603-A2 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use PC, PDK1, NOS3 KDM4E 2405/4885ALDH1A1 567/4885TDP1 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.